Lv5
1590 积分 2021-10-22 加入
Tumor-draining lymph nodes - friend or foe during immune checkpoint therapy?
6小时前
待确认
Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology
6小时前
待确认
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
1个月前
已完结
Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study
1个月前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
1个月前
已完结
Real-world comparison of chemo-immunotherapy and chemotherapy alone in the treatment of extensive-stage small-cell lung cancer
2个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
2个月前
已完结
Navigating first-line therapies for extensive-stage small-cell lung cancer: a frequentist network meta-analysis and systematic review
3个月前
已完结
The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population
3个月前
已完结
皖公网安备34019202002308
